Completed PHASE3 INTERVENTIONAL NCT00433368

Efficacy of L-Ornithine-L-Aspartate in Cirrhotics With Hepatic Encephalopathy

Efficacy of a Three Days' Infusion of L-Ornithine-L-Aspartate as an Adjuvant Therapy in Cirrhotic Patients With Overt Hepatic Encephalopathy: A Placebo Controlled Study

Sponsor: Aga Khan University

Conditions Hepatic Encephalopathy

Interventions L-Ornithine L-Aspartate

Updated 5 times since 2017 Last updated: Feb 8, 2007 Started: Oct 31, 2003 Completion: Sep 30, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Hepatic Encephalopathy and is currently completed. Aga Khan University leads this study, which shows 5 recorded versions since 2003 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Sep 2020 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Sep 2020 [monthly]

Completed PHASE3

First recorded

Oct 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Aga Khan University

Data source: Aga Khan University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Karachi, Pakistan